Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?

Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company's brain cancer drug. The bullish call has put the spotlight on the biotech's lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.

After losing to the Rays in the ALCS, Cleveland is headed home with major questions about several core players

The Rays acquired Peralta from the Mets at the trade deadline and his turnaround has propelled them to the World Series

The division is 0-6-2 since Week 5

Japanese slugger Teruaki Sato is eyeing a move to MLB after a dominant season. Could the 27-year-old spark a bidding war among baseball’s biggest franchises?